Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded enzyme and transporter findings by polarity

Inspect every admitted source sentence for an exact medicine, enzyme or transporter, and recorded role, with assertions, denials, and unresolved polarity counted separately.

What this does not mean: This is not a drug interaction checker. A denial applies only to the named medicine, role, counterparty, conditions, and source sentence; it is not proof of no interaction and is not dosing or treatment advice.
Public rows
8,404
Generated
Schema version
1.3.0

Coverage

What this run contains

Medicine–counterparty–role groups
8,404
Source sentence records
20,358
Asserted sentences
4,700
Denied sentences
7,494
Polarity not recorded
8,164
Medicines represented
755
Counterparties represented
36
Corpus records considered
9,855
All corpus records were checked; a record without a documented counterparty cannot produce a row in this projection.
inducer groups
617
inhibitor groups
3,131
not_recorded groups
3,074
substrate groups
1,582

Method

How the rows were made

  1. A deterministic parser reads recorded FDA-label excerpts for named enzymes and transporters.
  2. A mention is admitted only when the stored excerpt contains the recorded counterparty, allowing letter-case differences only.
  3. Every admitted mention is grouped by exact medicine slug, recorded counterparty spelling, and exact role. A missing role remains NOT_RECORDED rather than being assigned to another group.
  4. Each sentence carries the exact source version and effective date when recorded; the API serializes null and the page says not recorded when either is absent.
  5. The API paginates groups. Within each returned group, sentences is the complete untruncated list used by the three polarity counts.

Limits

Read these before using a row

  • A recorded role is a mechanistic statement copied from a descriptive label section. It is not a clinical interaction, and nothing in this dataset describes what happens when a person is exposed to two medicines at once.
  • This dataset holds no relation between one medicine and another. Counts are per counterparty; the medicines naming a counterparty are listed with their sentences and are never paired, ranked against each other or compared.
  • ICH M12 states that no potency classification system exists for transporters or for non-CYP enzymes, so no strong, moderate or weak vocabulary is applied to any counterparty here. The tallies count records, not strength.
  • A counterparty with a high count is one that labels document often. Documentation frequency is not importance: US labelling asks for some enzymes to be characterised far more routinely than others, and that requirement is part of what these counts measure.
  • 40.1% of admitted mentions carry no role. The sentence named more than one role and the parser left the question open rather than attaching a guess, so a role tally is a count of sentences that settled the question, not of medicines for which it is settled.
  • Recorded spellings are counted separately and never merged. P-GP, PGP and P-GLYCOPROTEIN are three entries in this dataset because they are three strings in the corpus; whether they name one thing is a question for a person, and prefix relationships are reported as questions rather than resolved.
  • 9088 of 9855 records name no enzyme or transporter at all. That is an absence of recorded text in the sources fetched for those records. It is neither reassurance nor alarm about the medicines concerned.
  • 20358 of 20358 admitted mentions come from records the deterministic label parser produced, where no person chose the value or wrote its measurement context. The sentence is stored with each one so a reader can check it.
  • The uniform reference for concentration allocates the same 20358 mentions over the same 36 counterparties by chance. Labels are not written that way, so the reference shows only that the observed spread is not a consequence of how many mentions there are.
  • The public rows enumerate documentation about one medicine and one named counterparty. They never create medicine-to-medicine pairs and cannot answer whether two medicines interact.
  • A NOT_RECORDED role or polarity remains unresolved. It is never folded into an assertion or a denial.
  • Each returned group includes every admitted source sentence for checking, but the full source document remains authoritative.

Provenance

Source examples

Abacavir · CYP3A4 inhibitor

2 asserted · 2 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
In vitro experiments reveal that abacavir does not inhibit human CYP3A4, CYP2D6, or CYP2C9 activity at clinically relevant concentrations.

Abacavir · BCRP substrate

0 asserted · 4 denied · 0 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Based on in vitro study results, abacavir at therapeutic drug exposures is not expected to affect the pharmacokinetics of drugs that are substrates of the following transporters: organic anion transporter polypeptide (OATP)1B1/3, breast cancer resistance protein (BCRP) or P-glycoprotein (P-gp), organic cation transporter (OCT)1, OCT2, or multidrug and toxic extrusion protein (MATE)1 and MATE2-K.

Abacavir · CYP2C9 not_recorded

0 asserted · 0 denied · 2 polarity not recorded

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
Abacavir did not inhibit or induce other CYP enzymes (such as CYP2C9, or CYP2D6).

Artifact used for this view: data/agents/current/enzyme-and-transporter-documentation.json. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
medicineNamestringRecorded medicine name; not normalized for display style.
counterpartystringThe exact recorded counterparty spelling.
rolestringSUBSTRATE, INHIBITOR, INDUCER, or NOT_RECORDED when the sentence did not settle one role.
assertedCountnumberSentence records whose polarity is ASSERTED.
deniedCountnumberSentence records whose polarity is NEGATED.
polarityNotRecordedCountnumberSentence records for which the parser did not settle assertion or denial.
sentencessentence[]Every admitted sentence for this group, with polarity, section, source identity, source version/effective date or explicit absence, retrieval date, and exact excerpt. The list is not truncated.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact recorded role.

Exact recorded counterparty spelling.

Clear

Showing 1,381–1,390 of 8,404 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 1381

    Medicine slug
    chenodiol
    Medicine name
    Chenodiol
    Enzyme or transporter
    OATP1B3
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.

  2. Projected row 1382

    Medicine slug
    chenodiol
    Medicine name
    Chenodiol
    Enzyme or transporter
    OCT1
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.

  3. Projected row 1383

    Medicine slug
    chenodiol
    Medicine name
    Chenodiol
    Enzyme or transporter
    OCT2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.

  4. Projected row 1384

    Medicine slug
    chenodiol
    Medicine name
    Chenodiol
    Enzyme or transporter
    P-GP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:015384e7-4ac5-4782-a309-e40cd1421c5b (opens source in a new tab)

      Chenodiol label

      Version not recorded · Effective date not recorded

      The glyco- and tauro- conjugates of chenodiol are high affinity substrates for BSEP, and in vitro studies suggest that chenodiol may inhibit OATP1B1 and OATP1B3 at the recommended dose of 250 mg TID (clinical significance unknown), but chenodiol and its glyco- and tauro- conjugates are not predicted to inhibit P-gp, BCRP, OATP2B1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K.

  5. Projected row 1385

    Medicine slug
    cholic-acid
    Medicine name
    Cholic Acid
    Enzyme or transporter
    BSEP
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-08-30
      FDA_LABEL:5c6e4c9d-b85e-493f-9420-ab2fd0ff3723 (opens source in a new tab)

      Cholic Acid label

      Version not recorded · Effective date not recorded

      Conjugated cholic acid is actively secreted into bile by the BSEP, and then released into the small intestines, along with other components of bile.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-08-30
      FDA_LABEL:5c6e4c9d-b85e-493f-9420-ab2fd0ff3723 (opens source in a new tab)

      Cholic Acid label

      Version not recorded · Effective date not recorded

      Conjugated cholic acid is actively secreted into bile by the BSEP, and then released into the small intestines, along with other components of bile.

  6. Projected row 1386

    Medicine slug
    choline
    Medicine name
    Choline
    Enzyme or transporter
    BCRP
    Role
    INHIBITOR
    Asserted sentences
    0
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. NEGATEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      It is not an inhibitor of P-gp, BCRP, MATE1/2-K, OATP1B1/3, OCT1/2 at the therapeutic dose range.
    2. NEGATEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      It is not an inhibitor of P-gp, BCRP, MATE1/2-K, OATP1B1/3, OCT1/2 at the therapeutic dose range.

  7. Projected row 1387

    Medicine slug
    choline
    Medicine name
    Choline
    Enzyme or transporter
    BCRP
    Role
    SUBSTRATE
    Asserted sentences
    2
    Denied sentences
    0
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Transporter systems: Diazoxide choline is a substrate for OAT1, OAT3, and BCRP.
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Transporter systems: Diazoxide choline is a substrate for OAT1, OAT3, and BCRP.

  8. Projected row 1388

    Medicine slug
    choline
    Medicine name
    Choline
    Enzyme or transporter
    CYP1A2
    Role
    INDUCER
    Asserted sentences
    2
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inducers Physiology-based pharmacokinetic model-based analysis suggests that concomitant use of VYKAT XR with rifampin (a strong CYP3A4 inducer and moderate CYP1A2 inducer) may decrease the C max and AUC inf of VYKAT XR by 14% to 30% and 40% to 70%, respectively, compared to VYKAT XR alone [see Drug Interactions (7) ] .
    2. ASSERTEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Strong CYP3A4 Inducers Physiology-based pharmacokinetic model-based analysis suggests that concomitant use of VYKAT XR with rifampin (a strong CYP3A4 inducer and moderate CYP1A2 inducer) may decrease the C max and AUC inf of VYKAT XR by 14% to 30% and 40% to 70%, respectively, compared to VYKAT XR alone [see Drug Interactions (7) ] .
    3. NEGATEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      It does not induce CYP1A2, CYP2B6 or CYP3A4 at the therapeutic dose range.
    4. NEGATEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      It does not induce CYP1A2, CYP2B6 or CYP3A4 at the therapeutic dose range.

  9. Projected row 1389

    Medicine slug
    choline
    Medicine name
    Choline
    Enzyme or transporter
    CYP1A2
    Role
    INHIBITOR
    Asserted sentences
    4
    Denied sentences
    2
    Polarity not recorded
    0
    Complete sentence records
    1. ASSERTEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Drugs That Inhibit CYP1A2 VYKAT XR is metabolized by CYP1A2 and coadministration with a strong CYP1A2 inhibitor may increase exposure of diazoxide and decrease concentrations of diazoxide metabolites.
    2. ASSERTEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      In Vitro Studies Enzyme systems: Diazoxide choline is an inhibitor of CYP1A2.
    3. ASSERTEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Drug Interaction Studies Drugs That Inhibit CYP1A2 VYKAT XR is metabolized by CYP1A2 and coadministration with a strong CYP1A2 inhibitor may increase exposure of diazoxide and decrease concentrations of diazoxide metabolites.
    4. ASSERTEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      In Vitro Studies Enzyme systems: Diazoxide choline is an inhibitor of CYP1A2.
    5. NEGATEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      In a clinical study with fluvoxamine (a strong CYP1A2 inhibitor), coadministration with fluvoxamine at an inhibitory dose increased single dose diazoxide C max by 17.5% and AUC 0-inf by 60% compared to the same parameter measured on single dose in the absence of fluvoxamine co-administration [see Drug Interactions (7) ] .
    6. NEGATEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      In a clinical study with fluvoxamine (a strong CYP1A2 inhibitor), coadministration with fluvoxamine at an inhibitory dose increased single dose diazoxide C max by 17.5% and AUC 0-inf by 60% compared to the same parameter measured on single dose in the absence of fluvoxamine co-administration [see Drug Interactions (7) ] .

  10. Projected row 1390

    Medicine slug
    choline
    Medicine name
    Choline
    Enzyme or transporter
    CYP1A2
    Role
    NOT_RECORDED
    Asserted sentences
    0
    Denied sentences
    0
    Polarity not recorded
    2
    Complete sentence records
    1. NOT_RECORDEDpharmacokineticsRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Elimination Metabolism Diazoxide is mainly metabolized by CYP1A2 and to a minor extent by CYP3A4.
    2. NOT_RECORDEDclinical_pharmacologyRetrieved 2026-09-12
      FDA_LABEL:0e745e85-9512-e360-e063-6394a90aebf1 (opens source in a new tab)

      Choline label

      Version not recorded · Effective date not recorded

      Elimination Metabolism Diazoxide is mainly metabolized by CYP1A2 and to a minor extent by CYP3A4.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/enzyme-transporter-negatives?limit=10&offset=1380

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
role
Exact recorded role.Values: INDUCER, INHIBITOR, NOT_RECORDED, SUBSTRATE
counterparty
Exact recorded counterparty spelling.
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy